Staphylococcus aureus News and Research

RSS

Staphylococcus aureus is a spherical bacterium (coccus) which on microscopic examination appears in pairs, short chains, or bunched, grape-like clusters. These organisms are Gram-positive. Some strains are capable of producing a highly heat-stable protein toxin that causes illness in humans.

AmpliPhi's novel bacteriophage therapy demonstrates comparable efficacy to vancomycin in S. aureus lung infection model

AmpliPhi Biosciences Corporation, a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced experimental results highlighting that its prototype bacteriophage cocktail demonstrated comparable efficacy to vancomycin in reduction of Staphylococcus aureus in a murine lung infection model.

22 Sep 2015

Study compares effectiveness of nafcillin and cefazolin in patients with MSSA blood stream infections

Research comparing clinical outcomes between patients receiving nafcillin and cefazolin for treatment of methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia shows that overall treatment failure rate among patients receiving cefazolin was no worse than nafcillin, and significantly fewer adverse effects were documented for those receiving cefazolin.

22 Sep 2015

New Locilex microbiology data presented at ICAAC/ICC 2015 scientific conference

Dipexium Pharmaceuticals, Inc., a late-stage pharmaceutical company focused on the development and commercialization of Locilex (pexiganan cream 0.8%), and research collaborators, JMI Laboratories, announced that new Locilex microbiology data were presented at the American Society for Microbiology's Interscience Conference of Antimicrobial Agents and Chemotherapy and International Society of Chemotherapy's International Congress of Chemotherapy and Infection (ICAAC/ICC 2015) scientific conference in San Diego, California, September 17-21, 2015.

21 Sep 2015

Combination of TXA709 and cefdinir demonstrates synergistic antibacterial activity against MRSA

TAXIS Pharmaceuticals, a drug-discovery company focused on developing a new class of antibiotic agents to treat life-threatening, multidrug-resistant bacterial infections, announced the presentation of results demonstrating the synergistic antibacterial activity of its lead clinical candidate, TXA709, when combined with cefdinir, a third-generation cephalosporin antibiotic.

19 Sep 2015

Tackling MRSA with bacteriophage

MRSA is bad news. If you've never heard of it, here's what you need to know: It's pronounced MER-suh, it's a nasty bacterial infection and it can cause serious disease and death.

15 Sep 2015

Three-drug strategy effective against drug-resistant staph infection, finds new research

Three antibiotics that, individually, are not effective against a drug-resistant staph infection can kill the deadly pathogen when combined as a trio, according to new research.

15 Sep 2015

Virginia Tech scientists discover new treatments to target antibiotic-resistant bacteria

Virginia Tech researchers have discovered a new group of antibiotics that may provide relief to some of the more than 2 million people in the United States affected by antibiotic resistance.

14 Sep 2015

Aridis' AR-301 granted FDA Fast Track Designation for treatment of pneumonia caused by S. aureus

Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel anti-infectives and immunotherapies for infectious diseases, announced today that the U.S. Food and Drug Administration granted Fast Track Designation to AR-301, the Company's fully human anti-Staphylococcal alpha-toxin IgG1 monoclonal antibody (mAb).

11 Sep 2015

Research opens up potential new pathways to vaccine development against HA-MRSA

New research led by NYU Langone Medical Center has uncovered why a particular strain of Staphylococcus aureus -- known as HA-MRSA -- becomes more deadly than other variations. These new findings open up possible new pathways to vaccine development against this bacterium, which the Centers for Disease Control and Preventions says accounts for over 10,000 deaths annually, mostly among hospital patients.

10 Sep 2015

Vestagen Technical Textiles completes $3.3 million convertible note bridge financing

Vestagen Technical Textiles, Inc., today announced that it has completed a $3.3 million convertible note bridge financing. Advent Life Sciences and HealthQuest Capital led the financing, and other existing Vestagen investors also participated.

9 Sep 2015

Antibiotic resistance awareness: an interview with Professor Colin Garner

The threat of antibiotic resistance is very real. It is estimated that 700,000 people die each from resistant infections. In Europe the figure is 25,000 deaths and a similar number in the USA.

7 Sep 2015

Researchers demonstrate successful eradication of multi-resistant bacteria from stables

Multi-resistant bacteria represent a major problem not only in hospitals but also in animal husbandry. A study of the University Bonn describes how a farmer successfully eliminated these pathogens entirely from his pig stable. However, the radical hygiene measures taken in this case can only be applied in individual cases. Nevertheless, the work has yielded a number of recommendations - not only for farms but also for hospitals. The study appeared in the Journal of Applied and Environmental Microbiology.

7 Sep 2015

FDA approves Allergan's sNDA to update label for TEFLARO (ceftaroline fosamil)

Allergan plc today announced the U.S. Food and Drug Administration has approved the company's supplemental new drug application (sNDA) to update the label for TEFLARO (ceftaroline fosamil) for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP).

2 Sep 2015

Researchers find that humans carry more antibiotic-resistant staphylococci than farm animals

Antibiotic-resistant bacteria are a concern for the health and well-being of both humans and farm animals. One of the most common and costly diseases faced by the dairy industry is bovine mastitis, a potentially fatal bacterial inflammation of the mammary gland (IMI). Widespread use of antibiotics to treat the disease is often blamed for generating antibiotic-resistant bacteria.

25 Aug 2015

Wyss Institute scientists develop improved blood-cleansing therapeutic device to treat sepsis

Last year, a Wyss Institute team of scientists described the development of a new device to treat sepsis that works by mimicking our spleen. It cleanses pathogens and toxins from blood circulating through a dialysis-like circuit. Now, the Wyss Institute team has developed an improved device that synergizes with conventional antibiotic therapies and that has been streamlined to better position it for near-term translation to the clinic.

21 Aug 2015

Surprising mechanism behind antibiotic resistant bacteria uncovered by TSRI scientists

Every year, more strains of bacteria develop resistance to the antibiotics we use to treat deadly infections. At The Scripps Research Institute (TSRI) scientists have been working to develop new forms of these drugs, including an antibiotic called arylomycin—but tests have shown that it is possible for bacteria to become resistant to arylomycin, too.

20 Aug 2015

Contact precaution use needs to be individualized to fit hospital's specific needs and resources

Contact precautions are recommended by the Centers for Disease Control and Prevention for all patients known to be infected with or carrying multidrug-resistant organisms (MDROs) such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE). Yet, the use of contact precautions--which require a patient to be isolated in a single hospital room and health care providers to wear a gown and gloves when caring for patients--is widely debated in the medical community.

19 Aug 2015

Duke specialist offers infection control measures to maintain health of pro football players

Keeping any team healthy is an important and daunting challenge, but the task is amplified in the National Football League when a bug that spreads rapidly through locker rooms and training facilities can impact an entire season.

14 Aug 2015

Dipexium reports net loss of $4.0 million for second quarter 2015

Dipexium Pharmaceuticals, Inc., a late-stage pharmaceutical company focused on the development and commercialization of Locilex (pexiganan cream 0.8%), a novel, broad-spectrum, topical antibiotic peptide, today reported financial results for the quarter ended June 30, 2015.

13 Aug 2015

AmpliPhi provides update on cGMP manufacturing facility and investigational bacteriophage cocktail for treating S. aureus

AmpliPhi BioSciences Corporation, a global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, announced that the Company will give a presentation today at the 21st Biennial Evergreen International Phage Meeting, taking place August 2-7 in Olympia, Wash.

6 Aug 2015